全文获取类型
收费全文 | 74226篇 |
免费 | 7418篇 |
国内免费 | 3228篇 |
专业分类
耳鼻咽喉 | 118篇 |
儿科学 | 4063篇 |
妇产科学 | 367篇 |
基础医学 | 5932篇 |
口腔科学 | 531篇 |
临床医学 | 6984篇 |
内科学 | 12995篇 |
皮肤病学 | 670篇 |
神经病学 | 1457篇 |
特种医学 | 1815篇 |
外国民族医学 | 7篇 |
外科学 | 28063篇 |
综合类 | 9797篇 |
现状与发展 | 16篇 |
一般理论 | 3篇 |
预防医学 | 1600篇 |
眼科学 | 1263篇 |
药学 | 3768篇 |
22篇 | |
中国医学 | 2978篇 |
肿瘤学 | 2423篇 |
出版年
2024年 | 79篇 |
2023年 | 1350篇 |
2022年 | 1515篇 |
2021年 | 3175篇 |
2020年 | 2988篇 |
2019年 | 3204篇 |
2018年 | 3155篇 |
2017年 | 2926篇 |
2016年 | 2898篇 |
2015年 | 2872篇 |
2014年 | 4851篇 |
2013年 | 5337篇 |
2012年 | 3770篇 |
2011年 | 4503篇 |
2010年 | 3981篇 |
2009年 | 3890篇 |
2008年 | 3995篇 |
2007年 | 4077篇 |
2006年 | 3977篇 |
2005年 | 3449篇 |
2004年 | 2851篇 |
2003年 | 2416篇 |
2002年 | 1988篇 |
2001年 | 1728篇 |
2000年 | 1378篇 |
1999年 | 1058篇 |
1998年 | 918篇 |
1997年 | 793篇 |
1996年 | 739篇 |
1995年 | 674篇 |
1994年 | 733篇 |
1993年 | 437篇 |
1992年 | 551篇 |
1991年 | 427篇 |
1990年 | 283篇 |
1989年 | 282篇 |
1988年 | 268篇 |
1987年 | 203篇 |
1986年 | 163篇 |
1985年 | 182篇 |
1984年 | 155篇 |
1983年 | 83篇 |
1982年 | 107篇 |
1981年 | 99篇 |
1980年 | 67篇 |
1979年 | 68篇 |
1978年 | 61篇 |
1977年 | 51篇 |
1976年 | 41篇 |
1975年 | 27篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
101.
Juan Tong HuiLan Liu ChangCheng Zheng XiaoYu Zhu BaoLin Tang Xiang Wan Wen Yao KaiDi Song Lei Zhang XuHan Zhang ZiMin Sun 《Pediatric transplantation》2020,24(2)
This is a retrospective study to evaluate the efficacy and safety of umbilical cord blood–derived mesenchymal stromal cells (MSCs) for the treatment of pediatric patients with severe BK virus–associated late‐onset hemorrhagic cystitis (BKV‐HC) after unrelated cord blood transplantation (UCBT). Thirteen pediatric patients with severe BKV‐HC from December 2013 to December 2015 were treated with MSCs. The number of MSCs transfused in each session was 1 × 106/kg once a week until the symptoms improved. The median follow‐up time was 1432 (89‐2080) days. The median frequency of MSC infusion was 2 (1‐3), with eight cured cases and five effective cases; the total efficacy rate was 100%. The copy number of urine BKV DNA was 4.43 (0.36‐56.9) ×108/mL before MSC infusion and 2.67 (0‐56.3) ×108/mL after MSC infusion; the difference was not significant (P = .219). There were no significant differences in the overall survival, disease‐free survival, and the incidence of relapse and acute and chronic graft‐versus‐host disease between the MSC infusion group and non‐MSC infusion group. There was also no significant difference in the cytomegalovirus, Epstein‐Barr virus (EBV), and fungal and bacterial infection rates between the two groups. Although umbilical cord blood–derived MSCs do not reduce the number of BKV DNA copies in the urine, the cells have a high efficacy rate and minimal side effects in treating severe BKV‐HC after UCBT among pediatric patients. MSCs do not affect the rates of relapse, long‐term infection, or survival of patients with leukemia. 相似文献
102.
103.
Valentina Becherucci Stefano Ermini Luisa Piccini Silvia Bisin Valentina Gori Francesca Gentile Riccardo Ceccantini Elena De Rienzo Barbara Bindi Paola Pavan Vanessa Cunial Elisa Allegro Francesca Brugnolo Daniela Maggio Daniela Calzolari Erika Maccarelli Silvia Galli Sonia Muricci Marco Berchielli Veronica Tintori Iacopo Sardi Franco Bambi 《Journal of clinical apheresis》2020,35(5):406-412
104.
105.
Acute kidney injury (AKI) to chronic kidney disease (CKD) progression has become a life-threatening disease. However, an effective therapeutic strategy is still needed. The pathophysiology of AKI-to-CKD progression involves chronic inflammation and renal fibrosis driven by macrophage activation, which is physiologically dependent on colony-stimulating factor-1 receptor (CSF-1R) signaling. In this study, we modulated macrophage infiltration through oral administration of the CSF-1R inhibitor GW2580 in an ischemia–reperfusion (I/R)-induced AKI model to evaluate its therapeutic effects on preventing the progression of AKI to CKD. We found that GW2580 induced a significant reduction in the number of macrophages in I/R-injured kidneys and attenuated I/R-induced renal injury and subsequent interstitial fibrosis. By flow cytometry, we observed that the reduced macrophages were primarily Ly6C+ inflammatory macrophages in the GW2580-treated kidneys, while there was no significant difference in the number and percentage of Ly6C−CX3CR1+ macrophages. We further found that these reduced macrophages also demonstrated some characteristics of M2-like macrophages, which have been generally regarded as profibrotic subtypes in chronic inflammation. These results indicate the existence of phenotypic and functional crossover between Ly6C+ and M2-like macrophages in I/R kidneys, which induces AKI worsening to CKD. In conclusion, therapeutic GW2580 treatment alleviates acute renal injury and subsequent fibrosis by reducing Ly6C+ M2-like macrophage infiltration in ischemia-induced AKI. 相似文献
106.
Tetsuo Mitsui Naoto Fujita Yuhki Koga Reiji Fukano Tomoo Osumi Asahito Hama Katsuyoshi Koh Harumi Kakuda Masami Inoue Takahiro Fukuda Hiromasa Yabe Junko Takita Akira Shimada Yoshiko Hashii Atsushi Sato Yoshiko Atsuta Yoshinobu Kanda Junji Suzumiya Ryoji Kobayashi 《Pediatric blood & cancer》2020,67(4)
107.
108.
109.
《Surgery (Oxford)》2020,38(7):368-374
Organ transplantation provides both life-saving and life-enhancing function for patients suffering from end-stage organ failure. Transplantation has only been possible due to the advances in immunosuppression. The viability of a transplanted organ depends on modulation of the human immune system to avoid rejection in response to foreign antigens. Modern immunosuppression consists of multi-modal therapy (chemical drugs and biological agents) acting on different parts of the immune response. Three phases of immunosuppression can be recognized: induction, maintenance and withdrawal. All patients must continue to take at least some immunosuppression to prevent rejection. Developments in immunosuppressant regimens have dramatically improved transplant success rates and experience over the years has helped to understand the side-effects and long-term complications of immunosuppression. Research continues to identify both novel compounds and ways of optimizing the use of current drugs. 相似文献
110.
《Actas urologicas espa?olas》2020,44(9):623-629
BackgroundTransplantation of kidneys with vascular anatomical variants remains a challenge. Due to its varying success in regard to graft function after transplantation, these organs have been frequently discarded assuming in advance an unaffordable rate of vascular complications.Patients and methodsWe performed three kidney transplants using organs from deceased donors harboring vascular variants (multiple arteries and short veins), including an unsplittable horseshoe kidney. Different grafts harvested from the same donor aorta, common iliac artery, and inferior vena cava, were used to reconstruct the initial vascular configuration by creating single arterial and venous conduits aimed to simplify the vascular anastomoses in the recipient.ResultsNo post-operative complications were recorded. Warm ischemia times remained comparable to single artery renal allografts. No delayed graft function was noted in any case, and every patient regained normal renal function after transplantation.ConclusionsVascular reconstruction using arterial and venous grafts harvested from the same deceased donor may result a helpful tool to simplify vascular anastomoses during transplantation surgery, thus avoiding their discard in advance, minimizing perioperative complications, and enabling normal graft function rates in the long-term follow-up. The successful outcome obtained by using this approach would help to expand the donor criteria for the inclusion of organs containing vascular anatomical variants. 相似文献